Diarrhea Workup
The diagnostic workup for diarrhea should be stratified by severity, duration, and clinical context—most patients with uncomplicated acute watery diarrhea require no testing, while those with alarm features (fever, bloody stools, severe dehydration, immunocompromise) need targeted stool studies and laboratory evaluation.
Initial Clinical Assessment
The first step is determining whether diagnostic testing is actually needed. For most immunocompetent patients with acute watery diarrhea (<14 days) without fever, blood in stool, or severe dehydration, no diagnostic workup is necessary 1. Testing should be reserved for specific high-risk scenarios.
When to Perform Diagnostic Testing
Indications for Stool Studies 2:
- Fever with diarrhea (suggests invasive bacterial pathogen)
- Bloody or mucoid stools (inflammatory/invasive process)
- Severe dehydration requiring hospitalization
- Immunocompromised patients (HIV/AIDS, transplant recipients, chemotherapy)
- Persistent diarrhea >14 days
- Recent international travel with fever or bloody diarrhea
- Suspected outbreak (multiple people affected)
- Recent antibiotic use (within 8-12 weeks—test for C. difficile)
- Ill-appearing young infants
Standard Stool Testing Panel 2:
When indicated, test one single stool sample for:
- Salmonella, Shigella, Campylobacter (bacterial culture)
- Yersinia enterocolitica (if right lower quadrant pain or pork exposure)
- Vibrio species (if rice-water stools or shellfish/brackish water exposure)
- Shiga toxin-producing E. coli (STEC)
- Clostridioides difficile toxin (if recent antibiotics)
- Norovirus (especially in outbreak settings)
Additional Testing for Specific Populations:
Immunocompromised patients 2:
- Broader parasitic evaluation: Cryptosporidium, Cyclospora, Cystoisospora, microsporidia
- Mycobacterium avium complex
- Cytomegalovirus (CMV)
- Viral studies
Travelers with persistent diarrhea ≥14 days 2:
- Parasitic examination: Giardia, Entamoeba histolytica
- Consider post-infectious irritable bowel syndrome
Severe/complicated cases 3:
- Complete blood count (CBC) with differential
- Comprehensive metabolic panel (electrolytes, renal function)
- Fecal leukocytes or lactoferrin (inflammatory marker)
- Blood cultures if sepsis suspected
Chronic Diarrhea Workup (>4 weeks) 4:
For continuous diarrhea persisting beyond 4 weeks, a more extensive evaluation is warranted:
First-line blood tests:
- Complete blood count (anemia, eosinophilia)
- Tissue transglutaminase IgA with total IgA (celiac disease)
- Thyroid-stimulating hormone (hyperthyroidism)
- C-reactive protein/erythrocyte sedimentation rate (inflammation)
Stool studies:
- Fecal calprotectin (inflammatory bowel disease screening)
- Stool culture and ova/parasites
- C. difficile testing if antibiotic exposure
- Fecal elastase (pancreatic insufficiency)
- 72-hour fecal fat collection (if steatorrhea suspected)
Endoscopic evaluation:
- Colonoscopy with biopsies (for inflammatory bowel disease, microscopic colitis)
- Upper endoscopy with duodenal biopsies (for celiac disease, tropical sprue, giardiasis)
Critical Pitfalls to Avoid
Do NOT routinely culture stool in uncomplicated acute watery diarrhea—this is expensive, low-yield, and delays appropriate supportive care 1.
Do NOT give antibiotics empirically to most patients with acute watery diarrhea—this can worsen outcomes, particularly with STEC infections where antibiotics increase hemolytic uremic syndrome risk 1.
Do NOT overlook C. difficile testing in patients with recent antibiotic exposure—even if symptoms began weeks after antibiotic completion 2.
Interpret multiplex PCR panels cautiously—these detect DNA, not necessarily viable organisms or clinically significant infections 2. Clinical context is essential.
For cancer treatment-induced diarrhea (grade 3-4), always obtain stool workup, CBC, and electrolyte profile when patients progress to severe symptoms 3.
Culture-independent diagnostic tests (CIDTs) that are positive should trigger reflex culture when public health reporting is required or antimicrobial susceptibility testing would guide management 2.
The key principle: tailor the workup intensity to the clinical severity and patient risk factors—avoid both over-testing low-risk patients and under-evaluating those with concerning features.